FDA New Dietary Ingredient notification is a key regulatory question for U.S. dietary supplement brands evaluating Akkermansia muciniphila. It is also one of the easiest areas to misunderstand.
For Akkermansia projects, the issue is not simply whether a supplier mentions "NDI." Brand owners, regulatory affairs teams, QA teams, R&D teams, legal teams, procurement teams, and contract manufacturers need to understand which strain, which ingredient form, which use level, which documentation package, and which finished-product route the notification supports.
Quick Answer
The pasteurized AKK PROBIO Akkermansia muciniphila ingredient has completed FDA New Dietary Ingredient Notification #1468. This notification is form-specific and should not be applied to the live form, other strains, or other Akkermansia ingredients without current documentation and regulatory review.
NDI notification is not FDA approval, certification, authorization, or endorsement. It is a premarket notification process for certain new dietary ingredients used in dietary supplements. Brands should still review the ingredient dossier, intended use, serving level, specifications, labeling, claims, and finished-product format before launch.
For AKK PROBIO, the relevant strain is Akkermansia muciniphila CGMCC No.20955. The pasteurized form is the form connected to NDI #1468. Both live and pasteurized forms are self-affirmed GRAS, but GRAS and NDI serve different regulatory functions.
What Is an FDA NDI Notification?
A New Dietary Ingredient notification is a premarket notification submitted to FDA that includes the basis for concluding that a dietary supplement containing the new dietary ingredient is reasonably expected to be safe under the conditions of use recommended or suggested in labeling.
For a brand team, NDI status is a documentation and review signal, not an approval claim or a substitute for finished-product assessment.
Important NDI review questions include:
- What is the exact ingredient?
- What is the strain identity?
- Is the ingredient live, pasteurized, or otherwise inactivated?
- What is the intended daily intake?
- What dose unit is used?
- What safety evidence supports the intended use?
- Does the notification cover the same form being purchased?
- Does the notification align with the brand's finished-product label directions?
- Does the supplier have current documentation that supports the intended project?
Why NDI Status Matters for Akkermansia
Akkermansia muciniphila is often positioned as a next-generation microbiome ingredient. It is not a legacy probiotic species with a long commercial history in every target format.
That makes regulatory readiness a major B2B review point. A supplement brand may be interested in the science, but a product cannot move smoothly through R&D, QA, legal, retailer review, and commercial planning unless the regulatory package is clear.
For Akkermansia, NDI status can affect:
- which ingredient form is selected;
- how the serving level is evaluated;
- which dose unit is used in specifications and label planning;
- which claims and label language are reviewed;
- what documents procurement requests from the supplier;
- how retailers, distributors, and legal teams assess risk;
- how practical the supplement launch pathway may be after regulatory, QA, and commercial review.
The strongest sourcing discussions begin with form-specific regulatory documentation, not with a generic species name. See How to Evaluate Akkermansia Ingredient Suppliers for the full procurement framework.
What AKK PROBIO NDI #1468 Covers
AKK PROBIO has completed FDA New Dietary Ingredient Notification #1468 for its pasteurized form, subject to review of the current supplier dossier.
That distinction is essential. NDI #1468 should be connected to the pasteurized Akkermansia muciniphila CGMCC No.20955 ingredient. It should not be generalized to other Akkermansia ingredients, other strains, or the live AKK PROBIO form unless current documentation and regulatory review support that use.
The pasteurized NDI context is described as 170 mg per day, equal to 3.4 x 10^10 TFU per day. Brands should confirm the current dossier, intended use, specifications, dose-unit definition, and label-use conditions before relying on this value for a finished product.
This value should not be treated as a universal serving recommendation for every formula, market, label claim, product format, or ingredient form.
NDI Notification Is Not FDA Approval
NDI notification should not be described as FDA approval, FDA certification, FDA authorization, or FDA endorsement.
A more accurate B2B phrasing is:
"The pasteurized AKK PROBIO form has completed FDA New Dietary Ingredient Notification #1468 — an FDA acknowledgment with no objection, not an approval."
For finished-product copy, regulatory teams should avoid approval-style or certification-style language, including:
- FDA-approved Akkermansia;
- FDA-certified Akkermansia;
- FDA-authorized probiotic or postbiotic;
- NDI-approved ingredient;
- language implying FDA has endorsed a self-affirmed GRAS conclusion;
- language that turns NDI notification into an approval claim.
These phrases can create unnecessary compliance risk because they overstate the meaning of an NDI notification or confuse it with other FDA programs.
NDI vs. GRAS for Akkermansia
NDI and GRAS are related to safety review, but they are not the same thing. They should not be used as substitutes for each other without regulatory review.
| Topic | FDA NDI Notification | Self-Affirmed GRAS |
|---|---|---|
| Primary context | Dietary supplement new dietary ingredient review | Food ingredient intended-use safety conclusion |
| Main question | Whether the dietary supplement containing the new dietary ingredient is reasonably expected to be safe under suggested labeling conditions | Whether the substance is generally recognized as safe under intended conditions of use |
| AKK PROBIO context | FDA NDI Notification #1468 applies to the pasteurized form only | Both live and pasteurized forms are self-affirmed GRAS |
| Form sensitivity | Form-specific; do not apply pasteurized-form NDI language to the live form without support | Tied to identity, intended use, conditions of use, and supporting documentation |
| Common mistake | Describing NDI notification as FDA approval, certification, authorization, or endorsement | Describing self-affirmed GRAS as FDA approval, FDA certification, or FDA endorsement |
| Buyer action | Verify the current NDI-related documentation, exact form, serving level, dose unit, and label-use conditions | Request the current GRAS summary or dossier and review it against the intended product category and use |
| Not interchangeable | NDI should not be used as a substitute for GRAS review | GRAS should not be used as a substitute for NDI review |
For U.S. product planning, brands should review both concepts, but they should not use one as a substitute for the other without regulatory review.
Live vs. Pasteurized Akkermansia
For Akkermansia, form matters. A live probiotic ingredient and a pasteurized postbiotic ingredient may share a strain origin, but they can have different regulatory, stability, dose-unit, specification, and labeling considerations.
AKK PROBIO offers both live and pasteurized forms of Akkermansia muciniphila CGMCC No.20955, and both forms are self-affirmed GRAS. However, the completed FDA NDI Notification #1468 is specific to the pasteurized form.
For B2B teams, the practical takeaway is straightforward: do not transfer the NDI status of the pasteurized form to the live form. A shared strain origin does not mean the same regulatory, stability, dose-unit, or labeling documentation applies to both forms. For the form-selection framework, see Live vs. Pasteurized Akkermansia.
What Brands Should Request From an Akkermansia Supplier
Before using NDI status in regulatory, QA, sales, customer-facing, or finished-product planning materials, brands should request a form-specific documentation package.
Useful documents may include:
- full strain identity and deposit information;
- specification sheet for the exact form;
- COA examples;
- safety summary and toxicology support;
- NDI documentation or NDI status summary, if relevant;
- GRAS summary or intended-use summary, if relevant;
- recommended serving level and dose-unit explanation;
- stability information relevant to the ingredient form;
- data or guidance for the intended finished-product format, where available;
- storage and handling guidance;
- labeling and claim-use guidance for regulatory review;
- allergen, GMO, contaminant, heavy-metal, and microbial testing information.
This review should happen before packaging, claim language, serving size, customer proposal language, or product positioning is locked.
How Brands Can Describe NDI Status Accurately
The safest public-facing approach is specific, factual, and limited to the relevant form.
A responsible wording pattern is:
"AKK PROBIO is Akkermansia muciniphila CGMCC No.20955, and the pasteurized form has completed FDA New Dietary Ingredient Notification #1468. Both live and pasteurized forms are self-affirmed GRAS. This should not be described as FDA approval, FDA certification, FDA authorization, or FDA endorsement."
This wording helps technical buyers understand the regulatory position without implying FDA approval.
Where AKK PROBIO Fits
AKK PROBIO is a documented Akkermansia ingredient for B2B teams that need regulatory, scientific, and formulation review.
For U.S. dietary supplement teams, relevant documentation points include:
- named strain identity: Akkermansia muciniphila CGMCC No.20955;
- completed FDA NDI Notification #1468 for the pasteurized form;
- self-affirmed GRAS status for live and pasteurized forms;
- live probiotic and pasteurized postbiotic options;
- scientific and evidence materials that should be reviewed against the intended claim area;
- U.S. distribution route through Maypro, subject to current verification.
The best use of this information is not to make broad regulatory or health claims. It is to support a clearer technical review process for product development, QA, regulatory, legal, and procurement teams.
FAQ
Does Akkermansia have an FDA NDI notification?
The pasteurized AKK PROBIO Akkermansia muciniphila form has completed FDA New Dietary Ingredient Notification #1468. This should not be generalized to all Akkermansia ingredients or to the live AKK PROBIO form.
Is NDI notification the same as FDA approval?
No. NDI notification is not FDA approval, certification, authorization, or endorsement. It is a premarket notification process for certain new dietary ingredients used in dietary supplements. Public claims should avoid approval-style and certification-style language.
Does AKK PROBIO NDI #1468 apply to live Akkermansia?
No. FDA New Dietary Ingredient Notification #1468 applies to the pasteurized AKK PROBIO form only. The live form should be reviewed separately and should not be described as covered by the same NDI notification unless current documentation and regulatory review support that use.
What dose unit is used for AKK PROBIO's pasteurized NDI context?
The pasteurized NDI context is described as 170 mg per day, equal to 3.4 x 10^10 TFU per day. Brands should confirm the current dossier, specification, intended use, dose-unit definition, and label-use conditions before relying on this information for a finished product.
What should regulatory teams review before using Akkermansia?
Regulatory teams should review strain identity, exact ingredient form, intended use, daily intake, NDI status, GRAS position, dose unit, specifications, safety evidence, stability information, label directions, and proposed claims.
Final Takeaway
For Akkermansia, NDI status is useful only when it is precise. Brands should identify the strain, confirm the ingredient form, review the dose unit, and avoid overstating the role of FDA.
For AKK PROBIO, the narrow and useful statement is that the pasteurized Akkermansia muciniphila CGMCC No.20955 form has completed FDA New Dietary Ingredient Notification #1468. That may provide a clearer starting point for U.S. dietary supplement review, but it does not replace finished-product regulatory, QA, labeling, claims, serving-level, and stability assessment.
Request the AKK PROBIO regulatory dossier
Planning a U.S. dietary supplement with Akkermansia? Request the current dossier →
Get the exact ingredient form, NDI-related documentation, GRAS summary, specification sheet, COA examples, and dose-unit guidance for review by your R&D, QA, regulatory, legal, and commercial teams.
Compliance Note
This article is intended for B2B ingredient education. It is not legal, medical, regulatory, or manufacturing advice. Regulatory status, serving level, label directions, specifications, stability expectations, and claims should be reviewed for the intended market, ingredient form, and finished-product format.
This content should not imply that Akkermansia ingredients diagnose, treat, cure, or prevent any disease. FDA New Dietary Ingredient notification should not be described as FDA approval, FDA certification, FDA authorization, or FDA endorsement. Self-affirmed GRAS should not be described as FDA approval, FDA certification, FDA authorization, or FDA endorsement.
References
- AKK PROBIO — Regulatory & Safety
- AKK PROBIO — Science & Evidence
- Maypro — AKK PROBIO Product Page
- FDA — New Dietary Ingredient (NDI) Notification Process
- FDA — Submitted 75-Day Premarket Notifications for New Dietary Ingredients
- FDA — Generally Recognized as Safe (GRAS)
- 21 CFR § 170.30. Eligibility for classification as generally recognized as safe